While 30–60% of breast cancer express mutations in the tumor suppressor p53 and approximately 10% express mutations in the polyposis syndrome tumor suppressor phosphatase and tensin homolog (PTEN), mutations in Neu/HER2 (ErbB2) are often found in conjunction with loss of function mutations in tumor suppressor proteins [17]. This evidence concerns the gene ERBB2 and breast carcinoma.